C-reactive protein as a risk predictor: Do race/ethnicity and gender make a difference?

Circulation

Volumn 114, Issue 5, 2006, Pages

  Albert, Michelle A ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; C REACTIVE PROTEIN; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PROGESTERONE; ROSUVASTATIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; BIOLOGICAL MARKER;

ADULT; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; ETHNIC DIFFERENCE; ETHNOLOGY; FAMILY HISTORY; FEMALE; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LABORATORY TEST; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN MODIFICATION; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; STROKE; AFRICAN AMERICAN; BLOOD; COMPARATIVE STUDY; EPIDEMIOLOGY; GENETICS; MALE; PHYSIOLOGY; PREDICTION AND FORECASTING; RISK FACTOR;

ADULT; AFRICAN AMERICANS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAUSALITY; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX FACTORS;

EID: 33747135785     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.613570     Document Type: Article

References (51)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Tex: American Heart Association; 2005.
2. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233-1241.
3. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff MA, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
6. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003;49:1258-1271.
7. Tillett WS, Francis T Jr. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561-571.
8. Calabró P, Willerson JT, Yeh ETH. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108:1930-1932.
9. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Andeson M, Savory J, Rifai N. Evaluation of nine automated high sensitivity C-reactive protein methods: implications for clinical and epidemiological applications: part 2. Clin Chem. 2001;47:418-425.
10. Koenig W, Sund M, Frölich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
11. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
12. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
13. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
14. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
15. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP. C-reactive protein and 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. Circulation. 2005;112:25-31.
16. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
17. Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109:1349-1353.
18. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Salonen JT. C-reactive protein in the prediction of cardiovascular mortality in middle aged men: a population based cohort study. Eur Heart J. 2005;26:1783-1789.
19. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation. 2003;108:161-165.
20. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Ciqui M, Fadel YY, Fortman SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application of clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
21. Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino DM. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem. 2003;49:1353-1357.
22. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713-716.
23. Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 1999;19:893-899.
24. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288:49-57.
25. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
26. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation. 1999;100:717-722.
27. Koh KK, Shin MS, Sakuma I, Ahn JY, Jin DK, Kim HS, Kim DS, Han SH, Chung WJ, Shin EK. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Aterioscler Thromb Vasc Biol. 2004;24:1516-1521.
28. Prestwood KM, Unson C, Kulldorff M, Cushman M. The effect of different doses of micronized 17beta-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci. 2004;59:827-832.
29. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2000;85:214-218.
30. Herrington DM, Brosnihan KB, Pusser BE, Seely EW, Ridker PM, Rifai N, MacLean DB. Differential effects of E and Droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab. 2001;86:4216-4222.
31. Post MS, van der Mooren MJ, Stehouwer CD, van Baal WM, Mijatovic V, Schalkwijk CG, Kenemans P. Effects of transdermal and oral estrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomized, placebo controlled trial. Thromb Haemost. 2002;88:605-610.
32. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837-842.
33. van der Meer IM, de Maat MPM, Kiliaan AJ, van der Kuip DAM, Hofman A, Witteman JCM. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003;163:1323-1328.
34. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem. 2004;50:574-581.
35. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol. 2004;93:1238-1242.
36. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH, Grundy SM, de Lemos JA. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46:464-469.
37. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore R, Pepys MB, Kooner JS. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation. 2001;104:145-150.
38. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein in body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001;25:1327-1331.
39. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, Lonn E, Teo K, McQueen M, Yusuf S. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol. 2004;24:1509-1515.
40. Yamada S, Tadao G, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, Kajii E. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population. Am J Epidemiol. 2001;153:1183-1190.
41. Yoshiike N, Kaneda F, Takimoto H. Epidemiology of obesity and public health strategies for its control in Japan. Asia Pac J Clin Nutr. 2002;11(suppl 8):S727-S731.
42. Saijo Y, Kiyota N, Kawasaki Y, Miyazaki Y, Kashimura J, Fukuda M, Kishi R. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes Obes Metab. 2004;6:249-258.
43. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-235.
44. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
45. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
46. Ferninand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, Barnes BO, Cox WR, Zieve FJ, Isaacsohn J, Ycas J, Sager PT, Gold A, for the ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six week trial. Am J Cardiol. 2006;97:229-235.
47. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
48. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P, for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
49. Ridker PM, on behalf of the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER Trial. Circulation. 2003;108:2292-2297.
50. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
51. Ridker PM, Cook NC. Should age and time be eliminated from cardiovascular risk prediction models? Circulation. 2005;111:657-658.